{"schema_version":"secwatch.filing_event.v1","accession":"0001860782-24-000074","form_type":"8-K","ticker":null,"cik":"0001860782","company_name":"2seventy bio, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.946206+00:00","generated_at":"2026-06-02T13:25:50.239407+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"2seventy bio Q1 revenue $12.4M, net loss $52.7M; FDA approved Abecma for earlier line; cash runway beyond 2027","bullets":["FDA approved Abecma for triple-class exposed R/R myeloma after 2+ prior lines; sLVV manufacturing approved.","Completed R&D pipeline divestiture to Regeneron, streamlining to focus solely on Abecma commercialization.","Total revenue $12.4M (down 70% YoY); net loss $52.7M vs $47M; collaborative arrangement loss $1.2M.","Costs reduced: R&D $43.9M (down 36% YoY); SG&A $12.7M (down 39% YoY); restructuring charges $4.2M.","Cash $181.4M; expect cash runway beyond 2027; anticipate Abecma return to growth in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001860782-24-000074","json":"https://secwatch.observer/filing/0001860782-24-000074.json","markdown":"https://secwatch.observer/filing/0001860782-24-000074.md","text":"https://secwatch.observer/filing/0001860782-24-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000074/0001860782-24-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000074/tvst-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T13:25:50.239407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cbbd5b2595b5792ae758b543791dbcb5332f52d9","claim":"2seventy bio, Inc. reported the first quarter ended March 31, 2024 results: revenue $12.4 million, net income $52.7 million.","evidence_excerpt":"Total revenues were $12.4 million for the three months ended March 31, 2024, compared to $41.6 million for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000074/0001860782-24-000074-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$12.4 million"},{"label":"Net income","value":"$52.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}